Gates-backed Waltham biotech Arsanis plots $58M IPO

After securing funding from GV, the Bill and Melinda Gates Foundation and other private investors, Waltham-based infectious disease biotech Arsanis has announced plans to tap into the public markets. The 39-employee company said in a federal filing on Friday that it hopes to raise up to $57.5 million in an initial public offering. Shares of Arsanis would trade under the ticker “ASNS.” So far in 2017, six Massachusetts-based biotechs have gone public. With the filing, Arsanis joins five ot hers…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news